Biotechnology Value Fund is a private investment partnership based in San Francisco, focusing on fundamentally-driven public biotechnology investments. Established in 1993, the fund aims to create concentrated, long-term investments in small-cap biotechnology firms. It emphasizes rigorous due diligence and continuous monitoring of its portfolio to ensure sustainable growth. Furthermore, Biotechnology Value Fund is dedicated to collaborating with its portfolio companies, fostering partnerships that support mutual success in the biotechnology sector.
Merida Biosciences is a biotechnology company specializing in the development of precision therapies for autoimmune diseases. It employs a protein engineering platform to create novel Fc therapeutics, which selectively target and neutralize specific antibodies, aiming to treat the root cause of antibody-driven diseases with high precision and durability.
Ikena Oncology
Post in 2024
Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.
Palvella Therapeutics
Post in 2024
Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.
Ambrosia Biosciences
Series A in 2024
Ambrosia Biosciences is a drug discovery company focused on developing small molecule-based therapies for obesity and other metabolic disorders. The company provides innovative, non-invasive methods for weight management and improving metabolic health, allowing patients to manage their conditions more effectively with fewer side effects than traditional medications. Through its research and development efforts, Ambrosia Biosciences aims to address the growing challenges associated with obesity and related metabolic issues.
Olema Oncology
Post in 2024
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.
Cidara Therapeutics
Post in 2024
Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.
Forte Biosciences
Post in 2024
Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company's lead product, FB-401, is a topically applied live biotherapeutic designed to treat inflammatory skin diseases, developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte Biosciences is advancing another product candidate, FB-102, which is a proprietary therapeutic molecule aimed at addressing a range of autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata. The company is currently in the preclinical trial stage for FB-102, reflecting its commitment to developing innovative treatments for dermatological and autoimmune disorders.
Eledon Pharmaceuticals
Post in 2024
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.
Inventiva Pharma
Post in 2024
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.
Bambusa Therapeutics
Seed Round in 2024
Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.
Ambrosia Biosciences
Series A in 2024
Ambrosia Biosciences is a drug discovery company focused on developing small molecule-based therapies for obesity and other metabolic disorders. The company provides innovative, non-invasive methods for weight management and improving metabolic health, allowing patients to manage their conditions more effectively with fewer side effects than traditional medications. Through its research and development efforts, Ambrosia Biosciences aims to address the growing challenges associated with obesity and related metabolic issues.
Celcuity
Post in 2024
Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer treatment through innovative diagnostics. The company's CELsignia diagnostic platform utilizes living tumor cells to uncover specific cellular processes that drive cancer in individual patients. This approach enables the identification of new cancer sub-types that traditional molecular diagnostics may overlook, ultimately expanding therapeutic options. Celcuity is developing the CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer and the CELsignia MP test for diagnosing 11 sub-types across various cancers, including breast, lung, colon, ovarian, kidney, and bladder. The company is also advancing its lead therapeutic candidate, gedatolisib, a pan-PI3K and mTOR inhibitor, currently being evaluated in a Phase 3 clinical trial for patients with advanced HR+/HER2- breast cancer.
Pheon Therapeutics
Series B in 2024
Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.
AltruBio
Series B in 2024
AltruBio is a biopharmaceutical company focused on developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases. Established in Delaware with its principal office in the San Francisco Bay Area, AltruBio integrates global resources to advance its research and development initiatives. The company has its roots in Taipei, Taiwan, where it has been working since June 2000 on discovering and developing novel therapeutics to address unmet medical needs. AltruBio employs a sophisticated discovery platform to identify and validate new antibody therapeutics. Currently, the company is developing several potential therapeutic antibodies that target a range of conditions, including autoimmune diseases and various types of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers, at different stages of development.
Eledon Pharmaceuticals
Post in 2024
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.
Immunic Therapeutics
Post in 2024
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.
Lassen Therapeutics
Series B in 2023
Lassen Therapeutics specializes in developing monoclonal antibodies aimed at treating fibrosis, rare diseases, and oncology. The company’s primary candidate, LASN01, targets the IL-11 receptor alpha, a critical component in the IL-6 family of cytokines. IL-11 is a significant mediator of fibrosis and plays an essential role in tumor growth and the organization of the tumor microenvironment. By blocking IL-11's activity, Lassen Therapeutics seeks to provide more effective treatment options compared to traditional approaches that target other factors like TGF-β and CTGF. Through innovative antibody technologies, the company aims to deliver breakthrough therapeutics that improve the lives of patients facing serious health challenges.
AC Immune
Post in 2023
AC Immune is a clinical-stage biopharmaceutical company based in Switzerland, dedicated to developing therapeutic and diagnostic products for neurodegenerative diseases linked to protein misfolding. Utilizing its proprietary technology platforms, the company creates antibodies, small molecules, and vaccines aimed at preventing and modifying these diseases. Its lead candidate, crenezumab, is a monoclonal antibody currently undergoing Phase II clinical trials for Alzheimer’s disease. Other notable candidates include ACI-24, an anti-Abeta vaccine in Phase II trials for Alzheimer’s and Down syndrome, ACI-35, an anti-Tau vaccine that has completed Phase Ib trials, and RG6100, an anti-Tau antibody in Phase II studies for Alzheimer’s patients. Additionally, AC Immune is exploring Tau Morphomer aggregation inhibitor small molecules and has diagnostics targeting various protein aggregates. The company has established collaborations with several prominent organizations, including Genentech and Biogen, and has a research partnership with the University of Pennsylvania focusing on TDP-43 in neurodegenerative diseases. Founded in 2003, AC Immune is headquartered in Lausanne, Switzerland.
Aro Biotherapeutics
Series B in 2023
Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.
Forward Therapeutics
Series A in 2023
Forward Therapeutics is a biopharmaceutical company focused on developing innovative oral small molecule therapies to treat chronic inflammatory disorders. The company's platform, driven by leading scientific expertise, enables the discovery and development of advanced treatments that aim to significantly improve patient outcomes and address unmet medical needs in this field.
Nimbus Therapeutics
Private Equity Round in 2023
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.
Olema Oncology
Post in 2023
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.
CG Oncology
Series F in 2023
CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.
Crossbow Therapeutics
Series A in 2023
Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies that mimic T-cells, which are essential components of the immune system, to target cancer cells with high precision. This next-generation approach allows for the assembly of immunotherapies that can reach previously inaccessible cancer cell targets, significantly broadening the scope of antibody therapy. By utilizing T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics aims to enhance the quality of life for cancer patients and unlock new therapeutic potentials across various types of cancer.
Quanta Therapeutics
Series D in 2023
Quanta Therapeutics is a biotechnology company focused on developing innovative cancer therapies targeting driver oncogenes, specifically RAS-driven cancers. The company employs advanced optical technology to discover small molecules that can modulate the conformation of RAS proteins. This allosteric modulation aims to restore conformational control of active RAS signaling at the cell membrane, thereby inhibiting a wide range of cancers associated with RAS mutations. By addressing the challenges of previously untreatable cancers, Quanta Therapeutics is committed to advancing new treatment options for patients and enhancing the understanding of RAS biology in cancer therapy.
Delcath Systems
Post in 2023
Delcath Systems, Inc. is an interventional oncology company based in New York that specializes in the treatment of primary and metastatic liver cancers. The company's primary product is Melphalan Hydrochloride for Injection, which is used in conjunction with the Delcath Hepatic Delivery System to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure and side effects. Delcath is currently conducting Phase III clinical trials, including the FOCUS Trial for patients with hepatic dominant ocular melanoma and the ALIGN Trial for intrahepatic cholangiocarcinoma. Additionally, Delcath offers Melphalan Hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System in Europe. Founded in 1988, Delcath Systems is dedicated to advancing treatment options for patients with liver cancer.
Unicycive Therapeutics
Post in 2023
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.
Verastem
Post in 2023
Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.
Palvella Therapeutics
Series D in 2023
Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.
Alpha9 Theranostics
Series B in 2022
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.
Aravive Biologics
Post in 2022
Aravive Biologics is a clinical-stage biotechnology company based in Houston, Texas, founded in 2008. The company specializes in developing novel cancer therapeutics aimed at treating various types of malignancies, including solid tumors and hematologic cancers. Aravive's approach involves targeting critical survival pathways, with a key therapeutic candidate designed to act as a decoy that binds to the GAS6 pathway with high affinity, thereby preventing the activation of the AXL signaling pathway. This strategy is intended to inhibit cancer cell growth and survival.
Immunic Therapeutics
Post in 2022
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.
Immunovant
Post in 2022
Immunovant, headquartered in New York, is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with autoimmune diseases. Its primary focus is on developing monoclonal antibodies, notably IMVT-1401, a fully human antibody that targets the neonatal Fc receptor (FcRn). This investigational product is designed for subcutaneous injection and aims to address various IgG-mediated autoimmune conditions. IMVT-1401 is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials also initiated for warm autoimmune hemolytic anemia. Additionally, the company is developing batoclimab and IMVT-1402, both targeting FcRn.
Nimbus Therapeutics
Venture Round in 2022
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.
Autobahn Therapeutics
Venture Round in 2022
Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.
Kymera Therapeutics
Post in 2022
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.
ESSA Pharma
Post in 2022
ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, established in 2009. The company is dedicated to developing innovative therapies for prostate cancer, particularly advanced stages of the disease. Its lead product candidate, EPI-7386, is an oral medication currently undergoing a Phase I clinical study aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's research focuses on small molecule drugs that selectively inhibit the N-terminal domain of the androgen receptor, a critical component for the growth and survival of prostate cancer cells. This strategic targeting represents a promising avenue for next-generation hormone therapy in the treatment of prostate cancer.
Dren Bio
Series B in 2022
Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.
Elektrofi
Series B in 2022
Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on advancing drug delivery methods to enhance patient experiences. Established in 2016, the company has developed a formulation system capable of processing a diverse array of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. Its innovative technology aims to improve subcutaneous administration, allowing drug manufacturers to create breakthrough therapies that empower patients with more control over how they receive essential medications.
MoonLake Immunotherapeutics
Post in 2022
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immunologic diseases. The company specializes in leveraging Nanobody technology to create new treatments aimed at addressing inflammatory conditions, particularly in the skin and joints. Its lead investigational product, Sonelokimab, represents a novel approach to managing inflammation, with the potential to significantly improve patient outcomes. Through its research and development efforts, MoonLake aims to advance the understanding and treatment of various inflammatory diseases, contributing to the evolving landscape of biopharmaceuticals.
Simcha Therapeutics
Series B in 2022
Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapies for cancer treatment. Based in New Haven, Connecticut, the company employs directed evolution to create novel cytokines aimed at enhancing the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor activity in animal studies, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. Founded in 2018, Simcha Therapeutics is dedicated to advancing innovative therapies that empower patients to effectively fight cancer.
Septerna
Series A in 2022
Septerna is a biotechnology company focused on discovering and advancing novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by integrating innovative drug discovery technologies with GPCR drug targets. Utilizing its Native Complex platform, Septerna facilitates industrial-scale drug discovery through advanced screening technologies and structure-based drug design. This approach enables medical researchers to efficiently identify treatments for a variety of diseases.
Third Harmonic Bio
Series B in 2022
Third Harmonic Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for severe allergies and inflammation. The company is focused on creating first-in-class oral small-molecule inhibitors targeting the KIT receptor, which plays a crucial role in the survival and function of mast cells—key immune cells involved in allergic responses. Its lead product candidate, THB001, is designed to provide selective inhibition of KIT, while another candidate, THB335, aims to address multiple mast cell-driven inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. Through its research and development efforts, Third Harmonic Bio seeks to advance the management of inflammatory diseases, enhancing patient outcomes and quality of life.
AN2 Therapeutics
Series B in 2022
AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.
Quanta Therapeutics
Series C in 2021
Quanta Therapeutics is a biotechnology company focused on developing innovative cancer therapies targeting driver oncogenes, specifically RAS-driven cancers. The company employs advanced optical technology to discover small molecules that can modulate the conformation of RAS proteins. This allosteric modulation aims to restore conformational control of active RAS signaling at the cell membrane, thereby inhibiting a wide range of cancers associated with RAS mutations. By addressing the challenges of previously untreatable cancers, Quanta Therapeutics is committed to advancing new treatment options for patients and enhancing the understanding of RAS biology in cancer therapy.
Alpine Immune Sciences
Post in 2021
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.
Nimbus Therapeutics
Venture Round in 2021
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.
Point Biopharma Global
Post in 2021
Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company leverages a portfolio of advanced radiopharmaceutical assets, expertise in radioisotopes like Actinium-225 and Lutetium-177, and innovative manufacturing technology. Point Biopharma Global's pipeline includes several promising candidates, such as PNT2002, PNT2004, PNT2003, and PNT2001, aiming to revolutionize theragnostic drug development and radioligand commercialization.
KAHR
Venture Round in 2021
KAHR Medical Ltd. is an immuno-oncology drug development company based in Jerusalem, Israel, founded in 2005. The company focuses on creating fusion protein pharmaceuticals aimed at treating cancer and autoimmune diseases. KAHR develops innovative drugs such as DSP105 and DSP106, which facilitate T-cell mediated tumor destruction, and DSP107, which targets CD47 tumors to activate phagocytes while delivering an immune costimulatory signal. Utilizing a unique platform of multifunctional immuno-recruitment proteins, KAHR's technology aims to enhance immune system recognition of cancer cells, thereby addressing the challenge of cancer evasion. This approach represents a significant advancement in protein-based pharmaceuticals, expanding treatment options for patients facing these serious health conditions.
Numab
Series C in 2021
Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.
MoonLake Immunotherapeutics
Series A in 2021
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immunologic diseases. The company specializes in leveraging Nanobody technology to create new treatments aimed at addressing inflammatory conditions, particularly in the skin and joints. Its lead investigational product, Sonelokimab, represents a novel approach to managing inflammation, with the potential to significantly improve patient outcomes. Through its research and development efforts, MoonLake aims to advance the understanding and treatment of various inflammatory diseases, contributing to the evolving landscape of biopharmaceuticals.
Alpha9 Theranostics
Series A in 2021
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.
AltruBio
Series A in 2021
AltruBio is a biopharmaceutical company focused on developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases. Established in Delaware with its principal office in the San Francisco Bay Area, AltruBio integrates global resources to advance its research and development initiatives. The company has its roots in Taipei, Taiwan, where it has been working since June 2000 on discovering and developing novel therapeutics to address unmet medical needs. AltruBio employs a sophisticated discovery platform to identify and validate new antibody therapeutics. Currently, the company is developing several potential therapeutic antibodies that target a range of conditions, including autoimmune diseases and various types of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers, at different stages of development.
GH Research
Series B in 2021
GH Research PLC is a clinical-stage biopharmaceutical company that aims to transform the treatment of psychiatric and neurological disorders. The company is primarily focused on developing novel and proprietary therapies based on 5-MeO-DMT, a compound known as Mebufotenin, to address the needs of patients suffering from Treatment-Resistant Depression (TRD). Through its innovative approach, GH Research seeks to provide new therapeutic options for individuals who have not responded to conventional treatments.
Viracta Therapeutics
Post in 2021
Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.
Silence Therapeutics
Post in 2021
Silence Therapeutics plc is a biotechnology company based in London, specializing in the discovery and development of innovative RNA therapeutics. The company focuses on utilizing short interfering RNA (siRNA) technology to modulate gene expression and address various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. Its pipeline includes several product candidates, such as SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to reduce the risk of cardiovascular diseases. Silence Therapeutics has established strategic collaborations with major organizations, including AstraZeneca, to advance the development of siRNA therapeutics across multiple disease areas. The company leverages its proprietary genetic toolkit and delivery systems to optimize therapeutic outcomes, harnessing the body's natural biological mechanisms for effective treatment.
Day One Biopharmaceuticals
Series B in 2021
Day One Biopharmaceuticals is a clinical-stage biotechnology company that specializes in developing targeted cancer therapies for patients of all ages, with a particular focus on pediatric patients. Recognizing the advancements in cancer research, the company aims to create treatments that can benefit both children and adults diagnosed with genetically defined cancers. Day One Biopharmaceuticals prioritizes the rapid development of therapies to meet the urgent needs of families facing cancer diagnoses. Their lead product candidate, DAY101, is an oral, highly-selective pan-RAF kinase inhibitor designed to penetrate the brain, addressing a significant treatment gap in pediatric oncology. By licensing and acquiring promising products from research institutions and other companies, Day One Biopharmaceuticals strives to bring effective medicines to market for those impacted by cancer.
Shoreline Biosciences
Venture Round in 2021
Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline utilizes a proprietary technology platform that focuses on induced pluripotent stem cell (iPSC) differentiation and the genetic programming of the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, thereby improving their anti-cancer activity. In addition to NK cells, Shoreline is also advancing the development of iPSC-derived macrophages for oncology and disease-modifying therapies. The company's innovative solutions aim to provide healthcare professionals with effective and cost-efficient treatment options for patients facing serious health challenges.
Aileron Therapeutics
Post in 2021
Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.
Ikena Oncology
Series B in 2021
Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.
Gritstone bio
Post in 2020
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.
Aro Biotherapeutics
Series A in 2020
Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.
Dren Bio
Series A in 2020
Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.
Nimbus Therapeutics
Venture Round in 2020
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.
Rezolute
Post in 2020
Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.
Eledon Pharmaceuticals
Post in 2020
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.
Rain Oncology
Series B in 2020
Rain Oncology Inc. is a late-stage precision oncology company focused on developing therapies that target oncogenic drivers. The company employs a tumor-agnostic approach, selecting patients based on the underlying genetics of their tumors rather than their histological characteristics. Its leading product candidate, milademetan, is an oral small molecule inhibitor of MDM2, which plays a role in various cancers. In addition to milademetan, Rain Oncology is advancing a preclinical program aimed at inducing synthetic lethality in cancer cells through the inhibition of RAD52. This targeted strategy aims to improve treatment outcomes for patients who are genetically predisposed to benefit from these therapies.
ESSA Pharma
Post in 2020
ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, established in 2009. The company is dedicated to developing innovative therapies for prostate cancer, particularly advanced stages of the disease. Its lead product candidate, EPI-7386, is an oral medication currently undergoing a Phase I clinical study aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's research focuses on small molecule drugs that selectively inhibit the N-terminal domain of the androgen receptor, a critical component for the growth and survival of prostate cancer cells. This strategic targeting represents a promising avenue for next-generation hormone therapy in the treatment of prostate cancer.
Olema Oncology
Series B in 2020
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.
Molecular Partners
Post in 2020
Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.
Cogent Biosciences
Post in 2020
Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).
Autobahn Therapeutics
Series B in 2020
Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.
Palvella Therapeutics
Series C in 2020
Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.
Surface Oncology
Private Equity Round in 2020
Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is advancing a pipeline of monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, targeting CD73; SRF617, aimed at CD39; SRF388, which targets interleukin 27; and SRF813, focused on CD112R. Additionally, Surface is exploring earlier-stage programs that address critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established collaborations with notable partners, including Novartis Institutes for Biomedical Research for cancer therapy development and Merck Sharp & Dohme Corp. to assess the safety and efficacy of combining SRF617 with KEYTRUDA, an anti-PD-1 therapy. Founded in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology aims to create conditions that enhance anti-tumor immune responses through its targeted approaches in cancer immunotherapy.
Kymera Therapeutics
Series C in 2020
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.
ALX Oncology
Series C in 2020
ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.
Inventiva Pharma
Post in 2020
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.
Syndax Pharmaceuticals
Post in 2020
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.
Infinity Pharmaceuticals
Post in 2020
Infinity Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing innovative treatments for various cancers. The company's lead candidate, eganelisib, is an oral immuno-oncology therapy that aims to reprogram macrophages to counteract immune suppression in cancer. Infinity is conducting multiple clinical trials to evaluate eganelisib in combination with established therapies, including global studies such as MARIO-275, which tests eganelisib alongside Opdivo® in patients with urothelial cancer, and MARIO-3, which explores combinations with Tecentriq® and Abraxane® in triple-negative breast cancer as well as with Tecentriq and Avastin® in renal cell carcinoma. Additionally, Infinity is collaborating with Arcus Biosciences to test a novel regimen that combines eganelisib with etrumadenant and Doxil® for advanced triple-negative breast cancer patients. The company's research also encompasses treatments for hematologic malignancies and solid tumors, reflecting its commitment to addressing various oncological challenges.
Pieris Pharmaceuticals
Post in 2019
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of anticalin-based drugs. Anticalins are engineered proteins derived from naturally occurring lipocalins, which have the ability to bind and transport a variety of molecules. The company's clinical pipeline includes PRS-060, a drug candidate in Phase I trials for asthma and inflammatory diseases, and PRS-343, a bispecific protein also in Phase I trials for oncology. Additionally, Pieris is advancing PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development, and PRS-080, which targets hepcidin for treating iron deficiency in patients with chronic kidney disease, currently in Phase IIa trials. Pieris has established strategic partnerships with several organizations, including Les Laboratoires Servier and AstraZeneca, and engages in research collaborations with academic institutions such as the University of Pittsburgh. The company was incorporated in 2000 and aims to address high unmet medical needs across various therapeutic areas, including cancer and severe asthma.
Inventiva Pharma
Post in 2019
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.
Repare Therapeutics
Series B in 2019
Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.
Phathom Pharmaceuticals
Venture Round in 2019
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.
Third Harmonic Bio
Series A in 2019
Third Harmonic Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for severe allergies and inflammation. The company is focused on creating first-in-class oral small-molecule inhibitors targeting the KIT receptor, which plays a crucial role in the survival and function of mast cells—key immune cells involved in allergic responses. Its lead product candidate, THB001, is designed to provide selective inhibition of KIT, while another candidate, THB335, aims to address multiple mast cell-driven inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. Through its research and development efforts, Third Harmonic Bio seeks to advance the management of inflammatory diseases, enhancing patient outcomes and quality of life.
Relay Therapeutics
Series C in 2018
Relay Therapeutics, Inc. is a clinical-stage precision medicine company based in Cambridge, Massachusetts, focused on transforming the drug discovery process. The company employs a novel allosteric drug-discovery platform, known as Dynamo, which integrates advanced computational techniques with experimental methods to study protein motion and interactions. This innovative approach enables the identification and development of therapies targeting complex diseases, particularly in oncology. Relay Therapeutics is advancing a pipeline of product candidates, including RLY-1971, a small molecule inhibitor targeting SHP2, RLY-4008, a selective inhibitor of FGFR2 for advanced solid tumors, and RLY-PI3K1047, aimed at mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, the company aims to deliver life-changing therapies to patients by addressing previously intractable targets in precision oncology and genetic diseases.
Akero Therapeutics
Series B in 2018
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.
4D Molecular Therapeutics
Series B in 2018
4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing innovative gene therapy products to address unmet medical needs. The company utilizes targeted and evolved adeno-associated virus vectors to create a diverse portfolio of product candidates focused on ophthalmology, cardiology, and pulmonology. Among its key projects are 4D-125, currently in a Phase I/II clinical trial for X-linked retinitis pigmentosa; 4D-110, in a Phase I clinical trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is advancing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. Founded in 2013, the company is dedicated to transforming the treatment landscape in these therapeutic areas.
Olema Oncology
Series A in 2018
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.
Rain Oncology
Series A in 2018
Rain Oncology Inc. is a late-stage precision oncology company focused on developing therapies that target oncogenic drivers. The company employs a tumor-agnostic approach, selecting patients based on the underlying genetics of their tumors rather than their histological characteristics. Its leading product candidate, milademetan, is an oral small molecule inhibitor of MDM2, which plays a role in various cancers. In addition to milademetan, Rain Oncology is advancing a preclinical program aimed at inducing synthetic lethality in cancer cells through the inhibition of RAD52. This targeted strategy aims to improve treatment outcomes for patients who are genetically predisposed to benefit from these therapies.
MEI Pharma
Post in 2018
MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.
Inventiva Pharma
Post in 2018
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.
Rezolute
Convertible Note in 2018
Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.
IDEAYA Biosciences
Series B in 2018
IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.
ViewPoint Therapeutics
Series B in 2018
ViewPoint Therapeutics, a biotechnology company founded in 2014 and based in San Francisco, focuses on developing treatments for diseases caused by protein misfolding, particularly cataracts. The company is advancing its research on crystallin stabilizers, which are small molecules designed to prevent and treat age-related cataracts and presbyopia. These stabilizers have shown promise in preclinical models through a systematic screening and optimization process. By targeting protein misfolding, ViewPoint Therapeutics aims to provide effective therapies for common age-related disorders, including cataracts and neurodegenerative diseases, ultimately enhancing treatment options for physicians and their patients.
Relay Therapeutics
Series B in 2017
Relay Therapeutics, Inc. is a clinical-stage precision medicine company based in Cambridge, Massachusetts, focused on transforming the drug discovery process. The company employs a novel allosteric drug-discovery platform, known as Dynamo, which integrates advanced computational techniques with experimental methods to study protein motion and interactions. This innovative approach enables the identification and development of therapies targeting complex diseases, particularly in oncology. Relay Therapeutics is advancing a pipeline of product candidates, including RLY-1971, a small molecule inhibitor targeting SHP2, RLY-4008, a selective inhibitor of FGFR2 for advanced solid tumors, and RLY-PI3K1047, aimed at mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, the company aims to deliver life-changing therapies to patients by addressing previously intractable targets in precision oncology and genetic diseases.
BioLineRx
Post in 2017
BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company's development pipeline includes several therapeutic candidates, such as BL-8040, a peptide designed for treating solid tumors, hematological malignancies, and facilitating stem cell mobilization. Another key candidate is AGI-134, an immuno-oncology agent aimed at solid tumors. Additionally, BioLineRx has developed BL-5010, a proprietary pen-like applicator intended for the non-surgical removal of skin lesions. The company has established collaborations with prominent organizations, including MSD for cancer immunotherapy, MD Anderson Cancer Center to explore the combination of BL-8040 with KEYTRUDA in pancreatic cancer, and Genentech Inc. for studies involving BL-8040 and TECENTRIQ in solid tumors. Founded in 2003, BioLineRx is focused on addressing unmet medical needs and improving existing therapies in the pharmaceutical market.
Pieris Pharmaceuticals
Post in 2016
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of anticalin-based drugs. Anticalins are engineered proteins derived from naturally occurring lipocalins, which have the ability to bind and transport a variety of molecules. The company's clinical pipeline includes PRS-060, a drug candidate in Phase I trials for asthma and inflammatory diseases, and PRS-343, a bispecific protein also in Phase I trials for oncology. Additionally, Pieris is advancing PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development, and PRS-080, which targets hepcidin for treating iron deficiency in patients with chronic kidney disease, currently in Phase IIa trials. Pieris has established strategic partnerships with several organizations, including Les Laboratoires Servier and AstraZeneca, and engages in research collaborations with academic institutions such as the University of Pittsburgh. The company was incorporated in 2000 and aims to address high unmet medical needs across various therapeutic areas, including cancer and severe asthma.
AnaptysBio
Series D in 2015
AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing therapeutic antibodies for inflammation and immuno-oncology. The company’s key product candidates include Etokimab, an anti-IL-33 treatment for atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis; and several immune cell modulating antibodies, including checkpoint agonists for autoimmune diseases. AnaptysBio's pipeline features notable immuno-oncology candidates such as TSR-042 (anti-PD-1), TSR-022 (anti-TIM-3), and TSR-075 (anti-PD-1/LAG-3 bispecific). The company employs a proprietary platform based on somatic hypermutation for antibody discovery and optimization, addressing unmet medical needs in therapeutic applications. AnaptysBio has formed partnerships with various organizations, including TESARO and Celgene, to enhance its research and development efforts. Founded in 2005, AnaptysBio has established itself in the biotechnology sector as a developer of innovative therapies targeting significant health challenges.
Tobira Therapeutics
Convertible Note in 2015
Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.
Ziarco
Series B in 2014
Ziarco, Inc. is a biotechnology company founded in 2012 and based in Palo Alto, California. The company specializes in the development of therapeutic agents aimed at treating inflammatory and allergic diseases. Its primary focus is on inflammatory skin disorders, and its product pipeline includes a histamine H4 receptor antagonist program targeting various conditions such as asthma, allergic rhinitis, pruritus, skin diseases, and pain. Ziarco's innovations aim to provide effective treatment options for patients suffering from atopic dermatitis and psoriasis, enhancing their quality of life through improved therapeutic solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.